BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lux Capital Closes 3rd Fund at $245 Million


2/13/2013 8:23:26 AM

New York, NY and Palo Alto, CA – February 13, 2013 – Lux Capital (www.luxcapital.com), a leading venture capital firm, today announced the closing of its third fund, Lux Ventures III, with commitments totaling $245 million. The Fund was oversubscribed, surpassing its initial $200 million target, and is the firm’s largest to date. Limited Partners comprise a number of prominent global foundations, endowments, financial institutions, fund-of-funds, corporations, and family offices.

“We are incredibly fortunate to have the support of our existing investors, as well as welcoming new institutions as our partners in Lux Ventures III,” said Lux Capital General Partner Adam Kalish. “We all share the philosophy that a differentiated approach and willingness to make contrarian venture investments can drive superior results.”

“At Lux, we are sticking to our knitting to build a concentrated portfolio of extraordinary companies in unconventional areas,” said Lux Capital Co-Founder and Managing Partner Josh Wolfe. “Many of the themes and entrepreneurs we’re excited about—in 3D printing, metamaterials, robotics and breakthroughs in solid-state electronics—are non-obvious, and that’s by design. We believe the combination of brilliant entrepreneurs and deep scientific innovation drives immense industry shifts and profits. Both at Lux and our companies, we’re growing rapidly and calling for the boldest and brightest that want to invent and invest in the future.”

Lux recently opened a new office in Palo Alto. The firm also added three new Venture Partners to the team since raising its prior fund: Jeff Kindler, former Chairman & CEO of Pfizer; Jim Woolsey, former Director of the CIA; and Richard Foster, former Senior Partner at McKinsey.

Lux Ventures III is pursuing the same focused investment strategy within the Energy, Technology and Healthcare sectors – investments revealed to date include Gridco Systems, Kymeta, Kyruus, and Shapeways. The Fund is making seed investments from $100,000 up to commitments of $15 million over a company’s life. In addition to founding its own companies and backing brilliant entrepreneurs from inception, Lux will also focus on special situations and corporate spinouts. Lux’s prior fund Lux Ventures II closed in 2007, allocating its nearly $100 million in commitments to representative investments including Kurion, Transphorm, Cerulean, Genocea, Kala, and Everspin.

“Lux has been a valuable forward-thinking partner and investor in helping build Shapeways,” said Peter Weijmarshausen, co-founder and CEO of Shapeways. “Our motto is ‘Made in the Future’ and they’re among the few actually investing in it.”

“Lux has taken a creative and methodical approach to build the next great venture firm,” said Richard Robb, of CVF, LLC, an affiliate of Henry Crown & Company. “By leveraging a novel platform and employing a unique investment strategy, Lux is backing exciting companies and in the process has created a very special firm.”

About Lux Capital Management

Lux Capital Management is a leading venture firm focused on founding, seed and early stage investments in emerging technologies. Lux takes an active role in helping entrepreneurs build successful businesses inEnergy, Technology and Healthcare. The Lux investment team has founded more than 20 companies from scratch, including Caliper, Genocea, Illumina, Kala, Kurion, Lux Research, Nanosys, Neurocrine, and Vertex Pharmaceuticals. The firm is based in New York and Palo Alto. For more information please visit www.luxcapital.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES